Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3
Journal of Human Immunity · 04.05.2026 · 2 (3)
DOI: 10.70962/jhi.20250249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 27.03.2026. Verfasst von Ahmad Rayes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Immunology and Hematopoietic Cell Transplantation/Cellular Therapy Program, Primary Children's Hospital, University of Utah, Salt Lake City…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Cancer Institute.
Abstract (Originalsprache)
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a life-threatening monogenic inborn error of immunity caused by pathogenic variants in the FOXP3 gene. In this report, we describe the clinical and immunologic consequences of a novel FOXP3 variant in an infant with refractory IPEX syndrome. Rapid whole-genome sequencing revealed a missense variant c.1050C>G (p.Ile350Met) in the forkhead domain of FOXP3. FOXP3 expression was abrogated in the regulatory T cell (Treg) subset but was maintained at low levels in activated effector T cells. The frequency of Treg-specific demethylated region (TSDR)–demethylated T cells was within normal range at birth, but it increased to pathologically high levels at 2 wk of age, prior to manifestation of disease symptoms. These results support the clinical relevance of the TSDR-demethylated cell percentage in evaluation of disease activity in IPEX. This case highlights a severe form of IPEX syndrome refractory to multiple immunosuppressive agents and the importance of early immunological studies to verify the clinical significance of novel genetic findings.
Autor:innen und Institutionen
- Pediatric Immunology and Hematopoietic Cell Transplantation/Cellular Therapy Program, Primary Children's Hospital, University of Utah, Salt Lake City, UT, USA.
- Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.
- Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT, USA.
- Center for Definitive and Curative Medicine, Stanford University, Stanford, CA, USA.
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
ORCID-Profile: Ahmad Rayes, Akshaya Ramachandran, Michael A Pulsipher, J Gregory Dolan, Soohee Cho, Amanda K Johnson, Jessie L Alexander, Simon Borna, Rosa Bacchetta
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Cancer Institute
- Bonnie Uytengsu and family endowment
Zitieren
APA
Rayes, A., Ramachandran, A., Pulsipher, M. A., Dolan, J. G., Cho, S., Johnson, A. K., Alexander, J. L., Borna, S., & Bacchetta, R. (2026). Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3. Journal of Human Immunity, 2(3). https://doi.org/10.70962/jhi.20250249
Vancouver
Rayes A, Ramachandran A, Pulsipher MA, Dolan JG, Cho S, Johnson AK, et al. Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3. Journal of Human Immunity. 2026;2(3). doi:10.70962/jhi.20250249
BibTeX
@article{Rayes2026,
author = {Rayes, Ahmad and Ramachandran, Akshaya and Pulsipher, Michael A and Dolan, J Gregory and Cho, Soohee and Johnson, Amanda K and Alexander, Jessie L and Borna, Simon and Bacchetta, Rosa},
title = {Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3},
journal = {Journal of Human Immunity},
year = {2026},
volume = {2},
number = {3},
doi = {10.70962/jhi.20250249}
}
EUVIMED